Cyclic AMP response element-binding protein (CREB)

Molecular Classification

Transcription factor, Nuclear protein, Basic leucine zipper (bZIP) protein

Other Names

cAMP response element-binding protein, Cyclic AMP-responsive element-binding protein, CREB-TF, CREB1 (gene), CREB2 (ATF4), CREB3, CREB5, CREB3L1, CREB3L2, CREB3L3, CREB3L4

Disease Roles

CancerNeurodegenerative disease (e.g., Alzheimer's disease)Schizophrenia

Cyclic AMP response element-binding protein Overview

Cyclic AMP response element-binding protein (CREB) is a cellular transcription factor (nuclear protein) that binds to DNA sequences known as cAMP response elements (CRE, consensus sequence 5'-TGACGTCA-3′) to regulate transcription of downstream target genes[1][3][9]. Upon phosphorylation—primarily at Ser133 by kinases such as protein kinase A (PKA), Ca^2+/calmodulin-dependent kinases, and MAPKs—CREB recruits coactivators (notably CREB-binding protein, CBP), initiating or suppressing gene expression[2][3][5]. CREB controls the expression of genes involved in diverse biological processes including memory formation, neuronal plasticity, metabolic regulation (e.g., in the liver and adipose tissue), circadian rhythms, cell survival, proliferation, and differentiation[1][2][3][4][5]. CREB is ubiquitously expressed, highly conserved, and preferentially dimerizes via a leucine zipper domain. Dysregulation of CREB is implicated in several pathological processes, notably neurodegenerative diseases (such as Alzheimer's), cancer, and mental disorders such as schizophrenia and depression, making it a therapeutic target of high interest in multiple disease areas[1][3][5][8].

Mechanism of Action

Modulation (either enhancement or inhibition) of transcription of genes with cAMP response elements via influencing CREB phosphorylation, dimerization, and binding to DNA; agents that increase intracellular cAMP (e.g., via PKA activation) can enhance CREB activity[2][3]; experimental inhibitors prevent DNA binding or dimerization[5].

Biological Functions

Gene transcription regulation

Signal transduction

Neuronal plasticity

Long-term memory formation

Cell survival

Cellular differentiation

Circadian rhythm synchronization

Apoptosis

Cell proliferation

Cell cycle

Stress response

Metabolism

Disease Associations

Cancer

Neurodegenerative disease (e.g., Alzheimer's disease)

Schizophrenia

Mood disorders

Memory disorders

Other neurological and metabolic disorders

Safety Considerations

Off-target effects due to CREB's role in multiple fundamental cellular processes (including learning, memory, and cell survival)
risk of neuropsychiatric or cognitive effects
potential impact on cell cycle and proliferation (possible tumorigenic risk if dysregulated)
challenges with cell-type specificity[1][5][2]

Interacting Drugs

No direct small molecule drugs currently approved that specifically target CREB

indirect modulators include forskolin (adenylate cyclase activator)[2]

phosphodiesterase inhibitors[3]

experimental CREB inhibitors or peptide disruptors (research use)[1][5]

Associated Biomarkers

Biomarker
Phosphorylated CREB (pCREB, at Ser133; detectable by immunoassay)
altered CREB expression in disease tissues
CREB signaling gene expression profiles[1][5][3]